Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
September 20 2017 - 8:00AM
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a
Fortress Biotech (NASDAQ:FBIO) company, today announced that James
F. Oliviero, President and Chief Executive Officer of Checkpoint,
will present a company overview at the Ladenburg Thalmann 2017
Healthcare Conference on Tuesday, September 26, 2017 at 11 a.m.
EDT. The conference will be held at the Sofitel Hotel in New York
City.
A live audio webcast of the presentation will be
available on the Events page of the Investors & Media section
of Checkpoint’s website: www.checkpointtx.com.
About Checkpoint
TherapeuticsCheckpoint Therapeutics, Inc. (“Checkpoint”)
is a clinical-stage, immuno-oncology biopharmaceutical company
focused on the acquisition, development and commercialization of
novel, non-chemotherapy, immune-enhanced combination treatments for
patients with solid tumor cancers. Checkpoint’s broad pipeline
consists of fully-human, immuno-oncology and checkpoint inhibitor
antibodies licensed from the Dana-Farber Cancer Institute that
target programmed death-ligand 1 (“PD-L1”); glucocorticoid-induced
TNFR-related protein (“GITR”); and carbonic anhydrase IX (“CAIX”).
In addition, Checkpoint is developing three oral, small-molecule,
targeted anti-cancer agents that inhibit epidermal growth-factor
receptor (“EGFR”) mutations, the bromodomain and extra-terminal
(“BET”) protein BRD4, and poly (ADP-ribose) polymerase (“PARP”).
Checkpoint will also seek to expand its pipeline to create
additional proprietary combination therapies that leverage the
immune system and complementary mechanisms. Checkpoint is a
majority-controlled subsidiary of Fortress Biotech, Inc., and is
headquartered in New York City. For more information, visit
www.checkpointtx.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a
biopharmaceutical company dedicated to acquiring, developing and
commercializing novel pharmaceutical and biotechnology products.
Fortress develops and commercializes products both within Fortress
and through certain subsidiary companies, also known as Fortress
Companies. In addition to its internal development programs,
Fortress leverages its biopharmaceutical business expertise and
drug development capabilities and provides funding and management
services to help the Fortress Companies achieve their goals.
Fortress and the Fortress Companies may seek licensings,
acquisitions, partnerships, joint ventures and/or public and
private financings to accelerate and provide additional funding to
support their research and development programs. For more
information, visit www.fortressbiotech.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
growth strategy and product development programs, and any other
statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated are: the risk that Checkpoint will not
be able to advance its research programs; risks related to the
timing of starting and completing of clinical trials; risks
inherent in research and development activities; risks related to
its growth strategy; its ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
uncertainties relating to preclinical and clinical testing; its
dependence on third-party suppliers; its ability to attract,
integrate, and retain key personnel; the early stage of products
under development; its need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in Checkpoint’s
public filings and reports. Checkpoint expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contacts: Jaclyn JaffeCheckpoint Therapeutics,
Inc. (781) 652-4500 ir@checkpointtx.com
Fortress Biotech Media RelationsLaura Bagby6 Degrees(312)
448-8098lbagby@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024